A Phase II Clinical Study of SB-480848 in Dyslipidemic Patients - A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of SB-480848 to Evaluate the Efficacy and Safety.

Trial Profile

A Phase II Clinical Study of SB-480848 in Dyslipidemic Patients - A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of SB-480848 to Evaluate the Efficacy and Safety.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2016

At a glance

  • Drugs Darapladib (Primary)
  • Indications Dyslipidaemias
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Aug 2009 Actual patient number (107) added as reported by ClinicalTrials.gov.
    • 05 Aug 2009 Actual end date January 2009 added as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top